New Delhi: Home-grown COVID-19 vaccine Covaxin has shown to develop long-term antibody and T-cell memory responses 3 months after the shot in Phase-1 trials.
Bharat Biotech said the safety outcome in Phase-2 trial was found to be tolerable and it is expected that the antibodies produced will last for 6 to 12 months.
Memory T cells are antigen-specific T cells that stay in the body for a long term after an infection is eliminated. No serious adverse reaction was observed, the company said in a research paper.
Covaxin, now in Phase-3 trials, was tried on 380 healthy children and adults during the Phase-2 trials. As many as 13,000 volunteers have been recruited for Phase III trials and a total of 26,000 participants across multiple sites will be needed for the trials. AIIMS Delhi is recruiting more volunteers to join the trials.
Also Read: Vaccine To Fight New Coronavirus Strain Can Be Made In 6 Weeks If Required: BioNTech
Mumbai: Bollywood celebrities have often had funny, at times bizarre experiences, mostly involving hero-worshipping, demanding fans.…
Bhubaneswar: Police have arrested the owner of a Jatra (theatre) group for allegedly duping an…
Sanskriti Talwar Faridkot (Punjab): For the third consecutive year, Balwinder Singh of Mallan village in…
Bhubaneswar: Rain may play spoilsport in Christmas and New Year celebrations in Odisha as the…
New Delhi: Netflix showed the way, Amazon Prime Video is following in their footsteps. Come…
Hyderabad: Allu Arjun’s woes keep mounting. In a worrying development, protesters stormed Allu Arjun’s Jubilee…
This website uses cookies.